Overview

A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Status:
Completed

Trial end date:
2017-08-01

Target enrollment:

Participant gender:

Summary

Slow release formulation of latanoprost is compared for safety and pressure-lowering efficacy with topically administration of commercially available latanoprost in patient with glaucoma and ocular hypertension

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

ViSci Ltd.

Treatments:

Latanoprost
Ophthalmic Solutions
Tetrahydrozoline